115 related articles for article (PubMed ID: 8625883)
1. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption.
Jay PR; Centrella M; Lorenzo J; Bruce AG; Horowitz MC
Endocrinology; 1996 Apr; 137(4):1151-8. PubMed ID: 8625883
[TBL] [Abstract][Full Text] [Related]
2. Effect of oncostatin-M on proliferation and activity in osteoblastic MC3T3-E1 cells.
Shih C; Yen CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):710-6. PubMed ID: 10533301
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone.
Richards CD; Langdon C; Deschamps P; Pennica D; Shaughnessy SG
Cytokine; 2000 Jun; 12(6):613-21. PubMed ID: 10843736
[TBL] [Abstract][Full Text] [Related]
4. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
Malaval L; Liu F; Vernallis AB; Aubin JE
J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
[TBL] [Abstract][Full Text] [Related]
5. Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor.
Persson E; Souza PPC; Floriano-Marcelino T; Conaway HH; Henning P; Lerner UH
Front Immunol; 2019; 10():1164. PubMed ID: 31191537
[No Abstract] [Full Text] [Related]
6. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts.
Varghese S; Yu K; Canalis E
Am J Physiol; 1999 Mar; 276(3):E465-71. PubMed ID: 10070011
[TBL] [Abstract][Full Text] [Related]
7. Are LIF and related cytokines functionally equivalent?
Piquet-Pellorce C; Grey L; Mereau A; Heath JK
Exp Cell Res; 1994 Aug; 213(2):340-7. PubMed ID: 8050491
[TBL] [Abstract][Full Text] [Related]
8. Cloning and biological activity of murine oncostatin M.
Hara T; Ichihara M; Yoshimura A; Miyajima A
Leukemia; 1997 Apr; 11 Suppl 3():449-50. PubMed ID: 9209421
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M is a differentiation factor for myeloid leukemia cells.
Bruce AG; Hoggatt IH; Rose TM
J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
[TBL] [Abstract][Full Text] [Related]
10. Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein.
Gimble JM; Wanker F; Wang CS; Bass H; Wu X; Kelly K; Yancopoulos GD; Hill MR
J Cell Biochem; 1994 Jan; 54(1):122-33. PubMed ID: 8126083
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
[TBL] [Abstract][Full Text] [Related]
12. Soluble glycoprotein 130 (gp130) attenuates OSM- and LIF-induced cartilage proteoglycan catabolism.
Hui W; Bell M; Carroll G
Cytokine; 2000 Feb; 12(2):151-5. PubMed ID: 10671300
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.
Taguchi Y; Yamamoto M; Yamate T; Lin SC; Mocharla H; DeTogni P; Nakayama N; Boyce BF; Abe E; Manolagas SC
Proc Assoc Am Physicians; 1998; 110(6):559-74. PubMed ID: 9824538
[TBL] [Abstract][Full Text] [Related]
16. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
J Clin Invest; 1995 Sep; 96(3):1319-27. PubMed ID: 7657807
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants.
Hui W; Bell M; Carroll G
Cytokine; 1996 Jun; 8(6):495-500. PubMed ID: 8818547
[TBL] [Abstract][Full Text] [Related]
18. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.
Guihard P; Danger Y; Brounais B; David E; Brion R; Delecrin J; Richards CD; Chevalier S; Rédini F; Heymann D; Gascan H; Blanchard F
Stem Cells; 2012 Apr; 30(4):762-72. PubMed ID: 22267310
[TBL] [Abstract][Full Text] [Related]
19. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury.
Guihard P; Boutet MA; Brounais-Le Royer B; Gamblin AL; Amiaud J; Renaud A; Berreur M; Rédini F; Heymann D; Layrolle P; Blanchard F
Am J Pathol; 2015 Mar; 185(3):765-75. PubMed ID: 25559270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
